<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Proshares Ultra Nasdaq Cybersecurity — News on 6ix</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity</link>
<description>Latest news and press releases for Proshares Ultra Nasdaq Cybersecurity on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 13 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/proshares-ultra-nasdaq-cybersecurity" rel="self" type="application/rss+xml" />
<item>
<title>TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-20</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/tacti-004-phase-iii-study-in-first-line-nsclc-to-be-discontinued-following-futility-analysis-20</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE</description>
</item>
<item>
<title>SUMA Acquisition Corporation Announces Closing of $172,500,000 Initial Public Offering, Including Full Exercise of Underwriters’ Over-Allotment Option</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/suma-acquisition-corporation-announces-closing-of-dollar172500000-initial-public-offering-including-full-exercise-of-underwriters-over-allotment-option-18</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/suma-acquisition-corporation-announces-closing-of-dollar172500000-initial-public-offering-including-full-exercise-of-underwriters-over-allotment-option-18</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Las Vegas, Nevada, March 13, 2026 (GLOBE NEWSWIRE) -- SUMA Acquisition Corporation (NASDAQ: SUMAU) (the “Company”) today announced the closing of its initial</description>
</item>
<item>
<title>Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-10</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum-10</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development</description>
</item>
<item>
<title>SunPower Completes the Integration of Sunder Energy</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sunpower-completes-the-integration-of-sunder-energy-25</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sunpower-completes-the-integration-of-sunder-energy-25</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Integration Strengthens New Engine of Growth, Quality Standards, and Gains U.S. No 4 Spot OREM, Utah, March 13, 2026 (GLOBE NEWSWIRE) -- SunPower Inc.</description>
</item>
<item>
<title>Equillium Announces $35 Million Financing with RA Capital Management</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-19</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/equillium-announces-dollar35-million-financing-with-ra-capital-management-19</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected</description>
</item>
<item>
<title>U.S. Energy Corp. Reports 2025 Results and Highlights Transformation into Integrated Industrial Gas, Energy, and Carbon Management Platform</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-9</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/us-energy-corp-reports-2025-results-and-highlights-transformation-into-integrated-industrial-gas-energy-and-carbon-management-platform-9</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) -- U.S. Energy Corporation (NASDAQ: USEG, "U.S. Energy" or the "Company") today reported financial and operating</description>
</item>
<item>
<title>Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-42</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/elutia-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635c4-42</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix</description>
</item>
<item>
<title>Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-4</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update-4</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Achieved Regulatory Milestones for the MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Development Program: U.S. Food and Drug</description>
</item>
<item>
<title>SGN Announces BlockchAIn Has Signed LOI for 5 MW AI Infrastructure Deployment, Over $100 Million in Expected Contract Value During Initial Term</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sgn-announces-blockchain-has-signed-loi-for-5-mw-ai-infrastructure-deployment-over-dollar100-million-in-expected-contract-value-during-initial-term-16</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sgn-announces-blockchain-has-signed-loi-for-5-mw-ai-infrastructure-deployment-over-dollar100-million-in-expected-contract-value-during-initial-term-16</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Scottsdale, AZ, March 13, 2026 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports”, “SGN” or the “Company”) (NYSE American: SGN), in connection</description>
</item>
<item>
<title>Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-9</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments-9</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline</description>
</item>
<item>
<title>SAGT Launches SAGE AI, Secures USD 11 Million in Enterprise Contracts to Drive AI-Powered Restaurant Transformation Across Southeast Asia</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sagt-launches-sage-ai-secures-usd-11-million-in-enterprise-contracts-to-drive-ai-powered-restaurant-transformation-across-southeast-asia-15</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sagt-launches-sage-ai-secures-usd-11-million-in-enterprise-contracts-to-drive-ai-powered-restaurant-transformation-across-southeast-asia-15</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Next-Generation AI Platform Leverages Data from Thousands of Locations to Optimize Operations, Forecast Demand, and Capture Rapid Growth in Asia-Pacific’s</description>
</item>
<item>
<title>Beyond Oil Announces Results of Meeting of Shareholders</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/beyond-oil-announces-results-of-meeting-of-shareholders-16</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/beyond-oil-announces-results-of-meeting-of-shareholders-16</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, March 13, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech</description>
</item>
<item>
<title>SBC Medical to Announce Q4 and Full‑Year 2025 Financial Results</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-9</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/sbc-medical-to-announce-q4-and-fullyear-2025-financial-results-9</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>IRVINE, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management</description>
</item>
<item>
<title>Oxford Lane Capital Corp. Prices Preferred Stock Offering</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/oxford-lane-capital-corp-prices-preferred-stock-offering-31</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/oxford-lane-capital-corp-prices-preferred-stock-offering-31</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>GREENWICH, Conn., March 13, 2026 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq GS: OXLC, OXLCP, OXLCL, OXLCO, OXLCZ, OXLCN, OXLCI and OXLCG) (the</description>
</item>
<item>
<title>Purple Biotech Announces CEO Transition</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/purple-biotech-announces-ceo-transition-10</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/purple-biotech-announces-ceo-transition-10</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE</description>
</item>
<item>
<title>MicroCloud Hologram Inc. (NASDAQ: HOLO) 2025 Annual Performance Forecast: Investment Income Fluctuations Lead to Annual Loss, Core Business Maintains Steady Growth</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-14</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/microcloud-hologram-inc-nasdaq-holo-2025-annual-performance-forecast-investment-income-fluctuations-lead-to-annual-loss-core-business-maintains-steady-growth-14</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>SHENZHEN, China, March 13, 2026 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, has</description>
</item>
<item>
<title>New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/new-guardant-healthharris-poll-survey-shows-92percent-of-all-eligible-americans-believe-colorectal-cancer-blood-tests-should-be-accessible-and-covered-similar-to-medicare-1</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/new-guardant-healthharris-poll-survey-shows-92percent-of-all-eligible-americans-believe-colorectal-cancer-blood-tests-should-be-accessible-and-covered-similar-to-medicare-1</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Survey highlights barriers to colorectal cancer screening for adults 45 and over Overwhelming majority (92%) of Americans ages 45 and over believe</description>
</item>
<item>
<title>P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-4</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/p3-health-partners-schedules-fourth-quarter-and-full-year-2025-earnings-release-and-conference-call-4</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>HENDERSON, Nev.--(BUSINESS WIRE)-- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health</description>
</item>
<item>
<title>Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-8</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/purple-biotech-reports-fourth-quarter-and-full-year-2025-financial-results-8</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Focus shifted to development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific</description>
</item>
<item>
<title>Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company</title>
<link>https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-24</link>
<guid isPermaLink="true">https://6ix.com/company/proshares-ultra-nasdaq-cybersecurity/news/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramedcreating-diversified-biomedical-company-24</guid>
<pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
<description>Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed’s POD™ oral delivery technology</description>
</item>
</channel>
</rss>